Funds Advised by Permira Acquire Neuraxpharm from Funds Advised by Apax Partners
September 22, 2020
Funds advised by Permira have agreed to acquire the controlling stake in Neuraxpharm, a leading European specialty pharmaceuticals company focused on central nervous system (CNS) disorders, from funds advised by Apax Partners. Financial terms were not disclosed; Neuraxpharm had annual revenues in excess of €460 million and around 850 employees under Apax's ownership.
- Buyers
- Funds advised by Permira
- Targets
- Neuraxpharm
- Sellers
- Funds advised by Apax Partners
- Industry
- Pharmaceuticals
- Location
- Spain
- Transaction Type
- Buyout
Explore More
Related Acquisitions
-
Pharmanovia Acquires Global CNS Portfolio from Sanofi
September 18, 2023
Pharmaceuticals
Pharmanovia, a Triton Fund V portfolio company, has acquired an 11‑brand global central nervous system (CNS) portfolio from Sanofi, including Frisium (clobazam) and Gardenal (phenobarbital). The asset package, available in 60+ markets, expands Pharmanovia's neurology franchise and commercial footprint across markets such as Brazil, South Africa, France and Italy in a divestiture from Sanofi.
-
Apax Partners and Fremman Capital acquire co-controlling stakes in Palex Medical
August 1, 2023
Medical Devices
Funds advised by Apax Partners LLP and funds advised by Fremman Capital agreed to acquire co-controlling stakes in Palex Medical, with Fremman remaining an investor while some of its funds and other minority shareholders sell. Palex, a Sant Cugat del Vallès (Barcelona)-headquartered MedTech distributor with ~928 employees, will partner with Apax and Fremman to accelerate pan-European growth and international expansion; the deal is expected to close in Q4 2023 and financial terms were not disclosed.
-
Permira Makes Substantial Growth Investment in PharmaCord
June 6, 2024
Healthcare Services
Permira (via a company backed by Permira funds) has signed a definitive agreement to make a substantial growth investment in PharmaCord, a Jeffersonville, Indiana-based tech-enabled patient services provider for specialty pharmaceuticals. Founder and CEO Nitin Sahney and the management team will remain significant investors and operators; terms were not disclosed and the deal is expected to close by Q4 2024.
-
Permira Acquires Majority Stake in Boats Group from Apax Partners
December 29, 2020
E-Commerce
A company backed by the Permira funds has agreed to acquire a majority stake in Boats Group from funds advised by Apax Partners. Boats Group, a Miami-based online classifieds marketplace and technology provider for the recreational marine industry (brands include YachtWorld, Boat Trader and boats.com), will partner with Permira to expand internationally and develop new products and services; financial terms were not disclosed.
-
Apax Funds Takes Norva24 Group AB Private
May 19, 2025
Infrastructure
Apax Funds (acting through Nordahl BidCo AB) completed a recommended cash offer to take Norva24 Group AB (publ) private with acceptance from roughly 98% of shareholders. The transaction follows exits by existing investors including Valedo Partners and Nordstjernan after a period of strong organic growth and more than 50 add-on acquisitions that grew Norva24 to roughly NOK 4bn in revenue.
-
Permira Acquires Majority Stake in Acuity Knowledge Partners from Equistone
January 27, 2023
Professional Services
Funds advised by Permira have acquired a majority stake in Acuity Knowledge Partners from Equistone Partners Europe; Equistone will reinvest as a minority shareholder and Acuity's management remains significantly invested. Headquartered in London, Acuity is a provider of research, analytics and business intelligence to financial services firms worldwide; Permira plans to support further investment in teams, services and technology to drive growth and geographic expansion. The deal is subject to customary regulatory approvals and was expected to close in Q2 2023; financial terms were not disclosed.
Track M&A activity that matters to you
Get real-time deal alerts, build buyer lists with AI, and access our full acquisition database. Start your free trial today.